Regeneron has won a court ruling that will make it harder for U.S. authorities to win a lawsuit accusing it of paying illegal ...
Regeneron is also embroiled in a securities fraud class action lawsuit stemming from a significant stock price drop on October 31, 2024. Shares plunged $84.59 that day, wiping out approximately $9 ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Key Takeaways Teva Pharmaceutical Industries and partner Alvotech said the Food and Drug Administration agreed to review ...
Regeneron Pharmaceuticals' fourth quarter results beat my and Wall Street analysts' expectations. See why REGN stock is a top ...
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...
Regeneron Pharmaceuticals Inc. convinced the First Circuit to impose a higher causation standard in the government’s False Claims Act case alleging a drug kickback scheme, according to a Tuesday ...
NEW YORK CITY, NY / ACCESS Newswire / February 17, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law ...
Regeneron and Sanofi said an FDA green light would make Dupixent the first targeted medicine in the U.S. for bullous pemphigoid, a debilitating and relapsing skin disease with underlying type 2 ...
So far, five biosimilars that reference Eylea 2 mg have been approved by the FDA. Alvotech/Teva expect to regulatory approval ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback